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Since few years the obligation to provide access to Antiret-
roviral (ARV) drugs for HIV positive people living in
resource-limited countries has become consensual.
Numerous programs implemented by the different
United Nations Agencies (UNAIDS), through inter-gov-
ernmental collaborations, or through non-governmental
organizations (NGO) and private foundations, have been
funded in many Asian and African countries. The benefit
of the treatment of HIV/AIDS, which is not restricted to
the procurement of ARVs, is related to the quality of the
long-term patients monitoring (decline in AIDS deaths)
and to the efficacy of the prevention (decline in new HIV+
patients). Most of the programs manage a limited number
of patients (restricted funds), and the benefits are limited
according the needs of the helped countries. However,
programs, which are focusing on a limited number of
patients, can be of prime importance if they are integrated
to the sustained development and able to improve the
global level of the public health of the country.
Although political sanctions preclude Burma from con-
sistent international financial contributions to HIV/AIDS,
the first program to access ARV drugs for the HIV+/AIDS
patients in the public sector has been funded by a private
company: Yadana (Total and partners) and implemented
by an international NGO: the International Union
Against Tuberculosis and Lung Disease (IUTLD) also
called "The Union". The World Health Organization
(WHO) and the Ministry of Health of Myanmar support
this program. It started April 1st, 2005 at the General Hos-
pital (MGH) of Mandalay the second largest city of the
country where 7000 HIV+ patients are estimated to be in
need of ARVs. It aims at managing patients treated for
Tuberculosis (TB) and co-infected with HIV infection
(tuberculosis occurs in 75% of the HIV+ patients therefore
providing the opportunity to detect the HIV infection). At
of the end of April 2006: 1372 TB patients have been
offered and have accepted to be tested for HIV, among
whom 427 (32%) patients were found to be TB-HIV co-
infected. Fifty-six spouses/children were offered HIV Vol-
untary Confidential Counseling and Testing (VCCT). 28
were found to be HIV positive. Of the 455 (427 + 28)
patients diagnosed to be HIV-infected, over 300 are
already managed and over 150 patients are being pro-
vided ARVs. Although the program is limited, it has raised
the level of HIV+ patient management to the UNAIDS rec-
ommended level for the following reasons:
• Implementation of the VCCT in the public sector: For
the first time, the test is performed on anonymous basis in
a public hospital and uses 2 rapid tests.
￿ Decrease in the discrimination: The implementation of
the program moved the HIV testing site from the depart-
ment for sexual transmitted infections (STI) to the tuber-
culosis center. For the first time in the public sector HIV
testing is not linked anymore to STIs.
￿ Possibility to get HIV tested on voluntary basis without
being a patient at hospital and with obvious AIDS clinical
signs. People have now the opportunity to be tested and
know their serological status.
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￿ Drug exchange program: For the first time, ARV drugs
can be exchanged between the different NGOs and organ-
isms without a request to the government. This will dra-
matically decrease the risk of treatment disruptions.
￿ Promotion of a program coordinator: For the first time,
the technical decisions are decentralized and the coordi-
nator can deal directly with the members of the NGO
without referring to the government.
These conditions requested by the IntNGO and accepted
by the government during the implementation phase of
the program are now considered as regular practices at the
national level and are used in other AIDS and other dis-
ease related programs.
In Myanmar, the IntNGO has assisted the government in
promoting international recommendations in the patient
management. This coordinated action provides a frame-
work for a successful fight against the HIV/AIDS epidemic
in resources limited countries, which take into account
the sustained development and the general benefit to the
public health.